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i.org/1decision making. The prognostic signiﬁcance of exercise pulmonary hypertension (PH) in
patients with secondary mitral regurgitation (MR) remains unknown. The aim of the
present study was to assess the prognostic value of exercise PH in patients with secondary
MR and narrow QRS intervals. From 2005 to 2012, 159 consecutive patients with secondary
MR, narrow QRS intervals, left ventricular dysfunction (mean ejection fraction 36 – 7%),
and measurable systolic pulmonary arterial pressure (SPAP) during exercise echocardiog-
raphy were included. Resting and exercise PH were deﬁned as SPAP >50 and >60 mm Hg,
respectively. Exercise PH was more frequent than resting PH (40% vs 13%, p <0.0001). On
multivariate logistic regression, the independent determinants of exercise PH were resting
SPAP (p <0.0001), exercise MR severity (p <0.0001), and e0-wave velocity (p[ 0.004). The
incidence of cardiac events during follow-up was signiﬁcantly higher in patients with ex-
ercise PH compared with those without exercise PH (4 years: 40 – 7% vs 20 – 5%,
p <0.0001). Patients with exercise PH exhibited higher rates of cardiac events and death
than those with resting PH. In a multivariate Cox proportional hazards model, exercise PH
was independently associated with the occurrence of cardiac events (p <0.0001). In
conclusion, in patients with secondary MR, exercise PH is determined mainly by resting
SPAP, left ventricular diastolic burden, and exercise MR severity. Exercise PH is a powerful
predictor of poor outcomes, with a 5.3-fold increased risk for cardiac-related death during
follow-up. These results highlight the added value of exercise echocardiography in sec-
ondary MR.  2015 Elsevier Inc. All rights reserved. (Am J Cardiol 2015;-:-e-)In asymptomatic valvular heart disease, exercise pulmo-
nary hypertension (PH) was recently identiﬁed by our group
as a powerful marker of advanced risk for cardiac events.1,2
In secondary mitral regurgitation (MR), exercise systolic
pulmonary arterial pressure (SPAP) is determined mainly by
dynamic MR3 and is involved in the pathogenesis of acute
pulmonary edema.4 The most recent guidelines recommend
mitral valve surgery in asymptomatic patients with preserved
left ventricular (LV) ejection fractions and severe primary
MR, in the presence of exercise PH (a European Society of
Cardiology class IIb indication5). There is no overt indication
for surgery in patients with secondary MR and exercise PH,
but the European Society of Cardiology guidelines state that
exercise PH might be an additional motivation to perform
surgery in patients with moderate MR who undergo coronary
artery bypass graft surgery (level of evidence C). Never-
theless, the prognostic signiﬁcance of exercise PH in patients
with secondary MR remains unknown. The aim of the pre-
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cise PH is an independent predictor of the occurrence of
acute pulmonary edema, cardiac events, and mortality.
Methods
From 2005 to 2012, any patients with secondary MR and
chronic LV systolic dysfunction (LV ejection fraction
<45%) referred to our heart valve clinic to undergo exercise
stress echocardiography were screened for ischemia, exercise
tolerance, and dynamic hemodynamic alterations (increase in
MR severity, PH, increase in LV ﬁlling pressures) (n¼ 315).
Patients fulﬁlling the following inclusion criteria were
eligible to be included in this study: (1) chronic secondary
MR, (2) sinus rhythm, (3) narrow QRS interval (<120 ms),
and (4) measurable SPAP during exercise echocardiography.
Of note, 19 patients (6%) were excluded from the ﬁnal
analysis according to this last exclusion criterion, resulting in
a feasibility rate in the measurement of exercise SPAP of
94%. The ﬁnal studied population was composed of 159
consecutive patients with heart failure (mean LV ejection
fraction 36 7%, range 20% to 44%). All had been stable for
2 months, and none met the following exclusion criteria (1)
technically inadequate echocardiogram, (2) more than trivial
aortic regurgitation or mild or greater aortic stenosis or severe
tricuspid regurgitation, (3) history of myocardial infarction
<6 months, (4) atrial ﬁbrillation or ﬂutter, (5) evidence of
inducible ischemia, and (6) extensive myocardial ischemia
requiring coronary angiography and revascularization. None
of the patients were in New York Heart Associationwww.ajconline.org
Figure 1. Exercise-induced increase in MR and in SPAP. EF ¼ ejection fraction.
2 The American Journal of Cardiology (www.ajconline.org)functional class IV. All patients gave their informed consent,
and the local ethics committee approved the protocol.
The presence of hypercholesterolemia was deﬁned as
total plasma cholesterol level >6.2 mmol/L or the use of
cholesterol-lowering medications. Systemic hypertension
was deﬁned as the use of antihypertensive medications or
having known but untreated hypertension (blood pressure
140/90 mm Hg).
All echocardiographic parameters were obtained at rest
and at peak exercise in the same cycling semisupine position
(Vivid 7 or 9; GE Healthcare, Little Chalfont, United
Kingdom). All Doppler echocardiographic recordings were
stored on a dedicated workstation for subsequent off-line
analysis. For each measurement, 2 cardiac cycles wereaveraged. MR was quantiﬁed as previously described6
(Figure 1). Regurgitant volume (RV) and effective regur-
gitant oriﬁce area (EROA) area were calculated with stan-
dard formulas. The biplane method of discs summation
(modiﬁed Simpson’s rule) was applied to quantify LV end-
diastolic and end-systolic volumes and the LV ejection
fraction. From the mitral inﬂow, the E- and A-wave veloc-
ities, E-wave deceleration time, and E/A velocity ratio were
measured. Left atrial maximal volume was measured using
the modiﬁed Simpson’s rule. Using color tissue Doppler
imaging, peak velocities during early (e0) diastole obtained at
the level of septal and lateral annulus were averaged. The E/
e0 ratio was then calculated. SPAP was derived from the
regurgitant jet of tricuspid regurgitation using the systolic
Table 1













Age (years) 6511 6411 6610 0.27
Male gender 105 (66%) 62 (65%) 43 (68%) 0.63
Resting heart rate (bpm) 7512 7512 7411 0.70
Resting systolic blood pressure (mmHg) 12815 12714 12915 0.49
Exercise heart rate (bpm) 11313 11413 11312 0.84
Exercise systolic blood pressure (mmHg) 15319 15216 15422 0.70
Smoker 101 (63%) 59 (62%) 42 (67%) 0.50
Hypercholesterolemia 72 (45%) 44 (46%) 28 (44%) 0.86
Hypertension 70 (44%) 39 (41%) 31 (49%) 0.29
Diabetes 38 (24%) 75 (78%) 46 (73%) 0.46
NYHA class III 38 (24%) 21 (22%) 17 (27%) 0.56
Previous myocardial infarction 129 (81%) 79 (82%) 50 (79%) 0.84
Previous coronary artery bypass graft 28 (18%) 18 (19%) 10 (16%) 0.64
Medication
Angiotensin converting enzyme inhibitor 125 (79%) 76 (79%) 49 (78%) 0.83
b-blockers 119 (75%) 71 (74%) 48 (76%) 0.75
Nitrate 69 (43%) 43 (45%) 26 (41%) 0.66
Lasix 83 (52%) 49 (51%) 34 (54%) 0.72
Aldacton 48 (30%) 26 (27%) 22 (35%) 0.29
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Resting Left ventricular and left atrial parameters
Left ventricular end-systolic volume (mL) 9325 9426 9222 0.61
Left ventricular end-diastolic volume (mL) 14430 14531 14328 0.72
Left ventricular ejection fraction (%) 367 357 367 0.72
Wall motion score index 1.650.27 1.650.25 1.650.3 0.96
E-wave velocity (cm/s) 6924 7225 6522 0.047
A-wave velocity (cm/s) 6227 6326 6028 0.56
e’-wave velocity (cm/s) 5.01.8 5.51.8 4.21.4 <0.0001
E/e’ ratio 15.26.8 14.26.3 16.77.3 0.025
Left atrial area (cm2) 18.74.4 18.84.7 18.63.8 0.78
Resting mitral regurgitation severity
Effective regurgitant oriﬁce area (mm2) 1610 1510 1711 0.39
Regurgitant volume (mL) 1913 1813 1419 0.25
Resting systolic pulmonary arterial pressure (mmHg) 3710 339 4210 <0.0001
Exercise left ventricular and left atrial parameters
Left ventricular end-systolic volume (mL) 8227 8229 8125 0.71
Left ventricular end-diastolic volume (mL) 14332 14534 14029 0.27
Left ventricular ejection fraction (%) 4310 449 4311 0.46
Wall motion score index 1.470.32 1.470.31 1.490.34 0.73
E-wave velocity (cm/s) 10025 9924 10428 0.24
A-wave velocity (cm/s) 6726 7127 5923 0.12
e’-wave velocity (cm/s) 6.32.3 7.12.4 5.11.5 <0.0001
E/e’ ratio 188.4 15.78 21.57.7 <0.0001
Left atrial area (cm2) 19.94.7 19.74.7 20.34.7 0.46
Exercise mitral regurgitation severity
Effective regurgitant oriﬁce area (mm2) 2514 2111 3215 <0.0001
Regurgitant volume (mL) 3220 2719 4019 <0.0001
Exercise systolic pulmonary arterial pressure, mmHg 5517 4411 729 By design
Exercise induced changes
Exercise-induced increase in Effective regurgitant oriﬁce area 127 (79%) 72 (81%) 55 (96%) 0.006
Exercise-induced increase in regurgitant volume 118 (74%) 67 (77%) 52 (93%) 0.013
Exercise-induced no or reduced Left ventricular ejection fraction 6 (4%) 3 (3%) 3 (5%) 0.60
Valvular Heart Disease/Exercise PH in Secondary MR 3
Table 3
Relationship between exercise systolic pulmonary arterial pressure and
resting and exercise echocardiographic data
Variable Exercise Systolic Pulmonary
Arterial Pressure
r p








Left ventricular ejection fraction 0.03 0.67
Wall motion score index -0.07 0.41
E-wave velocity -0.10 0.20
A-wave velocity -0.05 0.49
e’-wave velocity -0.25 0.002
E/e’ ratio 0.13 0.10
Left atrial area -0.05 0.57
Resting MR severity
Effective regurgitant oriﬁce area 0.16 0.84
Regurgitant volume 0.08 0.34
Resting systolic pulmonary arterial
pressure
0.58 <0.0001







Left ventricular ejection fraction -0.01 0.92
Wall motion score index 0.04 0.62
E-wave velocity 0.06 0.44
A-wave velocity -0.02 0.91
e’-wave velocity -0.31 <0.0001
E/e’ ratio 0.26 0.001
Left atrial area 0.04 0.67
Exercise MR severity
Effective regurgitant oriﬁce area 0.34 <0.0001
Regurgitant volume 0.31 <0.0001
Figure 2. Relation between exercise-induced changes in SPAP and
exercise-induced changes in RV (A) and in EROA (B), stratiﬁed according
to resting MR severity (light blue dots denote resting EROA >20 mm2;
dark blue dots denote resting EROA 20 mm2).
4 The American Journal of Cardiology (www.ajconline.org)transtricuspid pressure gradient (Figure 1) and the addition of
10 mm Hg for right atrial pressure, as previously per-
formed.1,2 Resting PH and exercise PH were deﬁned as
SPAP >50 and >60 mm Hg, respectively. Right atrial
pressure was assumed to be constant from rest to exercise.
Beta blockers were withdrawn on the day of the test. A
symptom-limited graded bicycle exercise test was performed
in the semisupine position on a tilting exercise table. After an
initial workload of 25 W maintained for 2 minutes, the
workload was increased every 2 minutes by 25 W. Blood
pressure and a 12-lead electrocardiogram were recorded
every 2 minutes. Two-dimensional and Doppler echocar-
diographic recordings were available throughout the test.
Follow-up information was obtained from interviews with
the patients, their relatives, or their physicians. Clinical man-
agement was determined independently by the patient’s per-
sonal physician using all information available. The primary
end point was cardiac mortality. The combined end point
included the following: cardiac-related death, heart failure
decompensation (worsening heart failure requiring hospitali-
zation, acute pulmonary edema), need for cardiac resynchro-
nization therapy or implantable cardiac deﬁbrillator, or hearttransplantation. Nonfatal myocardial infarction was reported
in the population with histories of ischemic heart disease but
was not considered a PH-related event.
Continuous variables are expressed as mean  SD, unless
otherwise speciﬁed. Group comparisons for categorical var-
iables were obtained with chi-square tests and for continuous
variables with Student’s t tests. Probabilities of event-free
survival were obtained by Kaplan-Meier estimates for the
2 groups and then compared using a 2-sided log-rank test.
The impact of exercise PH on the occurrence of the end point
was assessed with Cox proportional hazards models in uni-
variate and multivariable analyses. Variables with a univar-
iate p values <0.10 were incorporated into the multivariate
models. We used penalized smoothing splines to illustrate
the association of SPAP as a continuous variable and the risk
for cardiac event.7 A p value <0.05 was considered to
indicate statistical signiﬁcance.
Results
The demographic and clinical data of the 159 included
patients are listed in Table 1. None of the patients, at the
Figure 3. Incidence of heart failure (HF) hospitalization, death, and com-
bined cardiovascular events in patients with resting PH versus exercise PH.
Figure 4. Incidence of combined cardiac events according to the presence or
not of exercise PH. Percentages reported in the graphs are the rates of
events at 2- and 4-year follow-up.
Figure 5. Overall survival according to the presence or not of exercise PH.
Percentages reported in the graphs are the rates of survival at 2- and 4-year
follow-up.
Table 4
Multivariable determinants of exercise systolic pulmonary arterial pressure





Age 0.099 0.091 0.277
Male gender 1.931 2.073 0.353
Resting systolic pulmonary arterial
pressure
0.947 0.096 <0.0001
Exercise effective regurgitant oriﬁce area 0.578 0.089 <0.0001
e’-wave velocity -1.258 0.429 0.004
Valvular Heart Disease/Exercise PH in Secondary MR 5time of the study, had suspected signiﬁcant coronary artery
disease requiring myocardial revascularization. The preva-
lence of exercise PH was signiﬁcantly higher than resting
PH (40% vs 13%, p <0.0001). There was no signiﬁcant
difference between patients with exercise PH and those
without exercise PH regarding demographic and clinical
data, as well as baseline medication (Table 1).
In the whole cohort, SPAP signiﬁcantly increased from
rest to exercise (þ19  13 mm Hg, p <0.0001). Patients
with exercise PH had statistically lower resting E- and
e0-wave velocities but higher E/e0 ratios (Table 2). Resting
SPAP was signiﬁcantly higher in the exercise PH group. Of
note, there was no signiﬁcant difference between the 2
groups regarding resting MR severity (Table 2). During
exercise, e0-wave velocity was lower in exercise PH group
compared with the no exercise PH group, resulting in
signiﬁcantly higher exercise E/e0 ratios. During exercise,
MR severity was available (i.e., quantiﬁable) in 120 patients
(75%); MR increased signiﬁcantly in the whole cohort
(EROA þ8.5  11 mm2, p <0.0001, and RV þ12  15 ml,
p <0.0001). Exercise (Table 2) and exercise-induced in-
crease in MR severity were signiﬁcantly higher in patients
with exercise PH than in those with no exercise PH
(EROA þ14  11 vs þ5  10 mm2, p <0.0001, and
RV þ19  16 vs þ8  14 ml, p <0.0001).
In simple linear regression, exercise SPAP was signiﬁ-
cantly correlated (Table 3) with resting and exercise e0-wave
velocity, resting SPAP, exercise E/e0 ratio, and exercise
EROA and RV. Of note, exercise-induced changes in SPAP
were well correlated with exercise-induced changes in RVand in EROA (Figure 2) Using multiple linear regression
analysis, resting SPAP, exercise EROA, and e0-wave
velocity were identiﬁed as independent determinants of
exercise SPAP (Table 4). Similar results were found when
exercise RV was included in the model instead of exercise
EROA (b ¼ 0.26  0.05, p <0.0001).
During a mean follow-up period of 35  11 months
(range 2 to 53), 38 patients experienced heart failure
decompensation, 6 underwent cardiac resynchronization
therapy or implantable cardiac deﬁbrillator placement, 1
underwent heart transplantation, 12 had recurrent myocardial
infarctions, and 23 died of cardiac causes. In the whole
cohort, the survival rates were 95  2% and 81  4% at 2
and 4 years, and the rates of cardiac events were 19  3%
and 37  5%. The rates of combined events were not
different between patients with and those without resting PH
(24% vs 36%, p ¼ 0.19), whereas exercise PH was
Table 5
Cox proportional Hazard model: determinant of death, heart failure hospitalization and combined cardiac event
Variable Model#1: Heart failure hospitalization Model#2: Death Model#3: Cardiac event
HR 95%CI p HR 95%CI p HR 95%CI p
Age 0.991 0.957-1.026 0.600 1.015 0.974-1.057 0.481 1.008 0.981-1.035 0.568
Gender 0.783 0.300-2.046 0.618 0.883 0.328-2.373 0.805 0.870 0.450-1.684 0.680
Left ventricular end-systolic volume 1.021 0.982-1.062 0.294 0.990 0.948-1.034 0.654 0.994 0.965-1.023 0.662
Left ventricular end-diastolic volume 1.006 0.973-1.040 0.735 1.020 0.984-1.057 0.286 1.026 1.002-1.051 0.037
e’-wave velocity 1.191 0.900-1.576 0.222 0.890 0.646-1.227 0.478 1.052 0.857-1.291 0.627
Exercise E/e’ ratio 1.040 0.987-1.096 0.140 0.987 0.931-1.046 0.656 1.026 0.987-1.066 0.188
Resting effective regurgitant oriﬁce area 1.001 0.962-1.042 0.945 1.035 0.992-1.081 0.111 1.011 0.982-1.040 0.463
Exercise pulmonary hypertension 3.770 1.517-9.370 0.004 5.337 1.754-16.242 0.003 3.691 1.878-7.252 <0.0001
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
Figure 6. Association between exercise SPAP and the overall mortality risk.
HRs (solid line) were estimated in a Cox univariate model.
6 The American Journal of Cardiology (www.ajconline.org)signiﬁcantly associated with a higher rate (62% vs 38%, p
<0.0001). In addition, patients with exercise PH exhibited
higher rates of cardiac events and death than those with
resting PH (Figure 3). The incidence of cardiac events during
follow-up was signiﬁcantly higher in patients with exercise
PH compared with those without exercise PH (Figure 4).
Similarly, patients with exercise PH demonstrated signiﬁ-
cantly reduced survival (Figure 5). Kaplan-Meier curve
analysis showed that resting PH was not signiﬁcantly asso-
ciated with cardiac-related death (p ¼ 0.12), heart failure
decompensation (p¼ 0.09), or combined events (p¼ 0.052).
This lack of statistical signiﬁcance was even more pro-
nounced after adjustment of age and gender.
In contrast, in a multivariate Cox proportional hazards
model, after adjustment for age and gender, exercise PH was
associated with heart failure decompensation, cardiac-related
death, or any combined cardiac event (hazard ratio [HR] 2.9,
95% conﬁdence interval [CI] 1.3 to 6.5, p ¼ 0.009; HR 5.7,
95% CI 2.1 to 15.5, p ¼ 0.001; and HR 3.2, 95% CI 1.8 to
5.9, p <0.0001, respectively). Using further adjustment for
LV volumes, resting and exercise diastolic function, and
resting MR severity, exercise PH remained systematically
associated with higher risk for event or death (Table 5). In
this ﬁnal model, the addition of exercise EROA led to similar
results with an independent association between exercise PHand the combined end point (HR 2.05, 95% CI 1.03 to 4.05,
p ¼ 0.04). The relation between exercise SPAP and the risk
for combined cardiac events was assessed using the spline
function (Figure 6). The previous suggested threshold of
exercise SPAP >60 mm Hg to deﬁne PH was conﬁrmed in
the present cohort of patients with secondary MR (Figure 6).
The risk for cardiac events during follow-up increased
exponentially with the level of exercise SPAP, becoming
signiﬁcant at >60 mm Hg. Beyond 70 mm Hg (n ¼ 7) and
80 mm Hg (n ¼ 5), the risk for events increased by 50% (HR
from 1 to 1.5) and 100% (HR from 1 to 2), respectively. In
patients with resting EROA <20 mm2 (n ¼ 110), exercise
PH was signiﬁcantly associated with increased occurrence
of heart failure decompensation (p ¼ 0.025), rate of car-
diovascular events (p ¼ 0.003), and reduced survival
(p ¼ 0.015) compared with patients without exercise PH.Discussion
The results of our study show that exercise PH (1) is
frequent (40%) in patients with secondary MR, narrow QRS
intervals, and severe LV systolic dysfunction; (2) is deter-
mined mainly by resting SPAP and e0-wave velocity, as well
as exercise EROA; and (3) is a powerful predictor of the
occurrence of heart failure decompensation, cardiac-related
death, or combined cardiovascular events.
Exercise PH (40%) was signiﬁcantly more frequent than
resting PH (13%) in our population. As in other studies, we
showed that exercise PH was related mostly to exercise
valvular lesion severity (i.e., MR severity) and LV ﬁlling
pressure and/or LV diastolic burden but not to New York
Heart Association class. Although these parameters were
highly predictive of PH, exercise PH emerged as a distinct
risk factor for major cardiovascular events. Therefore, as in
other valvular heart diseases, exercise PH can potentially
identify a subset of patients who are at higher risk.1,2,8,9
In secondary MR, the dynamic increase in MR is a major
determinant of the exercise augmentation in SPAP and of
exercise PH3,10; it is also involved in the pathogenesis of
acute pulmonary edema irrespective of LV function.11
During exercise, the abrupt increase in MR severity, even
if mild, may exceed the level of left atrial compliance and
pulmonary vascular recruitment and leads to a signiﬁcant
increase in SPAP up to PH. Although initially benign, such
a phenomenon, when repetitive, can gradually proceed to
Valvular Heart Disease/Exercise PH in Secondary MR 7left atrial dilatation, increased LV ﬁlling pressure, atrial
ﬁbrillation, right ventricular dysfunction, low-level exercise
dyspnea, and ﬁnally resting symptoms.12
Although prognostically robust, measurement of SPAP at
peak exercise weakly reﬂects the dynamic and kinetic
changes in pulmonary vascular resistance during exercise.
Lewis et al,13,14 using multipoint SPAP-ﬂow plots, showed
that patients with heart failure exhibiting a steeper slope or
depicting a “plateau” pattern—a steep increase in SPAP at
low workload followed by a ﬂat slope at higher exercise
load—had worse outcomes. However, this approach appears
less feasible in daily routine practice than the straightfor-
ward measurement of SPAP at peak exercise.
In our experience, exercise SPAP is a much more
reproducible and feasible parameters than exercise MR
severity. In this regard, we do not recommend systemati-
cally quantifying MR severity during exercise15,16 but rather
exercise SPAP. In addition, the relation between exercise
SPAP and maximal exercise capacity or respiratory gas
exchange analysis would be of great interest and still re-
quires further investigation.
The management of patients with chronic secondary MR
remains challenging. Although current guidelines advocates
mitral valve surgery in patients with severe secondary MR at
the time of coronary artery bypass grafting,5,17 mitral valve
repair does not represent a unanimous therapeutic option for
chronic moderate secondary MR. As suggested in the Eu-
ropean Society of Cardiology guidelines, exercise PH may
represent a further incentive for combined surgery. How-
ever, to date, data supporting such a recommendation are
still lacking.
Our results conﬁrm the deleterious effects of exercise PH
in patients with LV systolic dysfunction and secondary MR.
Exercise PH negatively inﬂuences the outcome irrespective
of the degree of secondary MR. It is associated with a 3.7-
fold increased risk for combined cardiac events and a
5.3-fold increased risk for cardiac-related death during
follow-up. Conversely, the lack of exercise PH confers a
good prognosis, with cardiac event rates of 91  3.5% at 2
years and 84  5% at 4 years. Therefore, the presence of
elevated exercise SPAP can unmask a subset of patients who
may beneﬁt from targeted therapeutic approaches. When
surgical revascularization is contemplated, combined mitral
valve repair might be beneﬁcial. For the other clinical con-
ditions, close monitoring, if possible in a heart valve clinic,18
and strict adherence to treatment guidelines for heart failure
are recommended.
Right atrial pressure was estimated at 10 mm Hg at rest
and during exercise. Resting right atrial pressure is exten-
sively variable among subjects. In addition, this estimation
may also miss the potential inﬂuence of exercise-induced
changes in right atrial pressure. Nevertheless, the noninva-
sive evaluation of right atrial pressure during exercise (i.e.,
when venous compliance is known to decrease) with
noninvasive methods such as Doppler echocardiography
remains difﬁcult, is probably subject to low accuracy, and is
not validated. Moreover, right atrial pressure is frequently
assumed to be 5 mm Hg in normal subjects19 and 10 mm Hg
in patients with heart disease.20 The calculation of multi-
point slope of the SPAP-ﬂow plots during exercise was not
performed. However, it is a very demanding approach toassess the pulmonary vascular adaptation to exercise. The
use of a 2-point SPAP-ﬂow slope presents inherent meth-
odologic limitations.
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